News
Kamada announces further investment
WEIZMANN SCIENCE PARK, NESS ZIONA, Israel—Kamada, the specialty bio-pharmaceutical company developing a new Alpha-1 augmentation therapy, announced that it has received an estimated NIS 2.7M from an investment made through the exercise of warrants held by GlenRock Israel.
